# Opioid Analgesic Drugs: Considerations for Benefit-Risk Assessment Framework Guidance for Industry - FDA Guidance Document

Source: https://www.globalkeysolutions.net/guidances/guidance-document/opioid-analgesic-drugs-considerations-for-benefit-risk-assessment-framework-guidance-for-industry/c20377b8-3086-48cf-be2b-b9cd12520573

> FDA guidance document: Opioid Analgesic Drugs: Considerations for Benefit-Risk Assessment Framework Guidance for Industry. Issue date: June 20, 2019. Get complete insights and analysis.

---

## Details

- Title: Opioid Analgesic Drugs: Considerations for Benefit-Risk Assessment Framework Guidance for Industry
- Communication Type: Guidance Document
- Product Type: drugs
- Office Name: Center for Drug Evaluation and Research
- Office URL: /offices/center-for-drug-evaluation-and-research/cd980d74-1cbf-4226-ba9a-9045324c236c
- Issue Date: 2019-06-20
- Comment Close Date: 2019-08-20
- Last Changed: 2020-05-15
- Docket Number: <a href="https://www.regulations.gov/docket/FDA-2019-D-1536">FDA-2019-D-1536</a>

## Related Documents

- [Psychedelic Drugs: Considerations for Clinical Investigations](https://www.globalkeysolutions.net/guidances/guidance-document/psychedelic-drugs-considerations-for-clinical-investigations/c22c8005-efa9-4373-893d-cf27911562b6)
- [Nonalcoholic Steatohepatitis with Compensated Cirrhosis: Developing Drugs for Treatment Guidance for Industry](https://www.globalkeysolutions.net/guidances/guidance-document/nonalcoholic-steatohepatitis-with-compensated-cirrhosis-developing-drugs-for-treatment-guidance-for-industry/71c114f5-4930-4cda-87ef-12936678931f)
- [Gastroparesis: Clinical Evaluation of Drugs for Treatment Guidance for Industry](https://www.globalkeysolutions.net/guidances/guidance-document/gastroparesis-clinical-evaluation-of-drugs-for-treatment-guidance-for-industry/4b7bc445-8e11-4ce8-a6d6-3439f06daab5)